137 related articles for article (PubMed ID: 33401971)
1. The diagnostic and clinicopathological value of trefoil factor 3 in patients with gastric cancer: a systematic review and meta-analysis.
Zhang CX; Wu CT; Xiao L; Tang SH
Biomarkers; 2021 Mar; 26(2):95-102. PubMed ID: 33401971
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis.
Im S; Yoo C; Jung JH; Choi HJ; Yoo J; Kang CS
Int J Med Sci; 2013; 10(2):133-40. PubMed ID: 23329884
[TBL] [Abstract][Full Text] [Related]
3. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis.
Dhar DK; Wang TC; Tabara H; Tonomoto Y; Maruyama R; Tachibana M; Kubota H; Nagasue N
Clin Cancer Res; 2005 Sep; 11(18):6472-8. PubMed ID: 16166422
[TBL] [Abstract][Full Text] [Related]
4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
5. Heparanase mRNA and Protein Expression Correlates with Clinicopathologic Features of Gastric Cancer Patients: a Meta- analysis.
Li HL; Gu J; Wu JJ; Ma CL; Yang YL; Wang HP; Wang J; Wang Y; Chen C; Wu HY
Asian Pac J Cancer Prev; 2015; 16(18):8653-8. PubMed ID: 26745132
[TBL] [Abstract][Full Text] [Related]
6. Impact of NPM, TFF3 and TACC1 on the prognosis of patients with primary gastric cancer.
Ding A; Zhao W; Shi X; Yao R; Zhou F; Yue L; Liu S; Qiu W
PLoS One; 2013; 8(12):e82136. PubMed ID: 24358147
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Trefoil Factor 3 Expression in Patients with Gastric Cancer.
Taniguchi Y; Kurokawa Y; Takahashi T; Mikami J; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Mori M; Doki Y
World J Surg; 2018 Dec; 42(12):3997-4004. PubMed ID: 30039286
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer.
Cao GD; Xu XY; Zhang JW; Chen B; Xiong MM
PLoS One; 2016; 11(12):e0168085. PubMed ID: 28005970
[TBL] [Abstract][Full Text] [Related]
9. Expression of trefoil factors and TWIST1 in colorectal cancer and their correlation with metastatic potential and prognosis.
Yusup A; Huji B; Fang C; Wang F; Dadihan T; Wang HJ; Upur H
World J Gastroenterol; 2017 Jan; 23(1):110-120. PubMed ID: 28104986
[TBL] [Abstract][Full Text] [Related]
10. TFF3 and survivin expressions associate with a lower survival rate in gastric cancer.
Meng JR; Tang HZ; Zhou KZ; Shen WH; Guo HY
Clin Exp Med; 2013 Nov; 13(4):297-303. PubMed ID: 22996285
[TBL] [Abstract][Full Text] [Related]
11. Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy.
Al-Salam S; Sudhadevi M; Awwad A; Al Bashir M
BMC Cancer; 2019 Feb; 19(1):135. PubMed ID: 30744593
[TBL] [Abstract][Full Text] [Related]
12. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.
Chen WM; Chen WD; Jiang XM; Jia XF; Wang HM; Zhang QJ; Shu YQ; Zhao HB
World J Gastroenterol; 2017 Sep; 23(33):6100-6110. PubMed ID: 28970725
[TBL] [Abstract][Full Text] [Related]
13. Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer.
Choi B; Lee HJ; Min J; Choe HN; Choi YS; Son YG; Ahn HS; Suh YS; Goldenring JR; Yang HK
Cancer Biomark; 2017 Jul; 19(3):231-239. PubMed ID: 28453457
[TBL] [Abstract][Full Text] [Related]
14. The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk.
Kaise M; Miwa J; Tashiro J; Ohmoto Y; Morimoto S; Kato M; Urashima M; Ikegami M; Tajiri H
J Gastroenterol; 2011 Jun; 46(6):736-45. PubMed ID: 21455714
[TBL] [Abstract][Full Text] [Related]
15. Association between Promoter Polymorphisms of TFF1, TFF2, and TFF3 and the Risk of Gastric and Diffuse Gastric Cancers in a Korean Population.
Jin EH; Lee SI; Kim J; Seo EY; Lee SY; Hur GM; Shin S; Hong JH
J Korean Med Sci; 2015 Aug; 30(8):1035-41. PubMed ID: 26240479
[TBL] [Abstract][Full Text] [Related]
16. Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer.
Lee JY; Park KS; Lee HG; Baek WK; Cho KB; Lee YJ; Lee YS; Ryu SW
Clin Exp Med; 2017 Aug; 17(3):403-410. PubMed ID: 27154568
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic significance of the RUNX3 expression in gastric cancer: a systematic review and meta-analysis.
Liu B; Han Y; Jiang L; Jiang D; Li W; Zhang T; Zu G; Zhang X
Int J Surg; 2018 May; 53():122-128. PubMed ID: 29578091
[TBL] [Abstract][Full Text] [Related]
18. The value of trefoil factor 3 expression in predicting the long‑term outcome and early recurrence of colorectal cancer.
Morito K; Nakamura J; Kitajima Y; Kai K; Tanaka T; Kubo H; Miyake S; Noshiro H
Int J Oncol; 2015 Feb; 46(2):563-8. PubMed ID: 25405728
[TBL] [Abstract][Full Text] [Related]
19. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening.
Aikou S; Ohmoto Y; Gunji T; Matsuhashi N; Ohtsu H; Miura H; Kubota K; Yamagata Y; Seto Y; Nakajima A; Goldenring JR; Kaminishi M; Nomura S
Gastroenterology; 2011 Sep; 141(3):837-845.e1-7. PubMed ID: 21699780
[TBL] [Abstract][Full Text] [Related]
20. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China.
Huang Z; Zhang X; Lu H; Wu L; Wang D; Zhang Q; Ding H
BMC Gastroenterol; 2014 Apr; 14():74. PubMed ID: 24720760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
